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Seven-Year Treatment Outcome of Entecavir in a
Real-World Cohort: Effects on Clinical Parameters,
HBsAg and HBcrAg Levels
Yuk-Fai Lam, MBBS1, Wai-Kay Seto, MD1,2, Danny Wong, PhD1,2, Ka-Shing Cheung, MBBS, MPH1, James Fung, MD1,2,
Lung-Yi Mak, MBBS1, John Yuen, BSc1,2, Chun-Kong Chong, MPhil1, Ching-Lung Lai, MD1,2 and Man-Fung Yuen, MD, PhD1,2
OBJECTIVES: We aimed to determine the levels of alanine aminotransferase (ALT), hepatitis B virus DNA (HBV DNA), HBsAg, and a
novel viral marker (hepatitis B core-related antigen (HBcrAg)); hepatitis B e antigen (HBeAg) seroconversion and drug resistance
rates after 7 years of entecavir treatment in chronic hepatitis B (CHB) patients.
METHODS: Two hundred and twenty-two Chinese CHB patients on continuous entecavir treatment were recruited. Serologic,
virologic, biochemical outcomes, and the occurrence of entecavir signature mutations were determined.
RESULTS: The rates of ALT normalization, HBeAg seroconversion, and undetectable HBV DNA were 98.3%, 82.1%, and 98.7%,
respectively, after 7 years of entecavir treatment. The genotypic resistance rate was 1.2%. Decline of HBsAg level was modest with
a median decline rate of 0.107 log IU/ml/year. Among patients with baseline HBsAgo1,000 IU/ml and annual HBsAg decline rate of
≥ 0.166 log IU/ml, all have HBsAg of o200 IU/ml (a level highly predictive for HBsAg seroclearance) at year 7. In contrast, in
patients with baseline HBsAg≥ 1,000 IU/ml and annual HBsAg decline rate ofo0.166 log IU/ml, 95.5% had HBsAg of≥ 200 IU/ml at
year 7. Decline of HBcrAg levels was moderate with a median decline rate of 0.244 log kU/ml/year. Forty-seven patients (32.0%) had
undetectable HBcrAg level at year 7.
CONCLUSIONS: Long-term entecavir therapy continued to have good responses with low drug resistance rate. However, the
decline of HBsAg with treatment was suboptimal. HBcrAg level declined at a relatively better rate. Baseline HBsAg level of
o1,000 IU/ml and annual decline of 0.166 log IU/ml could be used to predict HBsAg response.
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INTRODUCTION
Chronic hepatitis B (CHB) infection is a disease of major
health burden globally, with ~ 250 million people affected.1
Nucleos(t)ide analogs are the mainstay of therapy. Of these,
entecavir is the most widely used agent. Our previous study
showed that entecavir is highly effective in terms of potency of
viral suppression with low rate of viral resistance up to 5 years
of therapy.2 Long-term use of entecavir was also shown to
improve liver function, histology in patients with advanced
fibrosis/cirrhosis, and, more importantly, reduce the incidence
of hepatocellular carcinoma (HCC).3,4
While most of the CHB patients have undetectable hepatitis
B virus DNA (HBV DNA) while on entecavir, a proportion of
patients continued to develop complications while on
treatment.5 More serological markers other than HBV DNA
may help to monitor patients while on nucleos(t)ide analogs to
guide treatment and assess prognosis. Hepatitis B core-
related antigen (HBcrAg) is a novel marker that can detect
hepatitis B core antigen and hepatitis B e antigen (HBeAg)
simultaneously.6 HBcrAg was shown to correlate positively
with serum HBV DNA, intrahepatic total HBV DNA, and
hepatitis B covalently closed circular DNA (cccDNA).7,8 The
correlation between HBcrAg and cccDNA was also observed
in patients with negative serum HBV DNA.9 Previous studies
showed that HBV DNA decline more rapidly than serum
HBcrAg in patients treated with nucleoside analogs.10,11 As
most of the patients on long-term entecavir have undetectable
HBV DNA, serum HBcrAg level may be potentially useful to
reflect intrahepatic viral activity in this group of patients.
According to a recent study, HBcrAg levels are predictive of
development of HCC in patients with undetectable HBV DNA
under nucleos(t)ide analog therapy.12 High HBcrAg level was
also shown to be a predictive factor for reactivation of hepatitis
after cessation of lamivudine therapy,13,14 development of
lamivudine resistance,15 and post-treatment recurrence of
HCC during anti-viral therapy.16
Quantitative HBsAg level has been recently studied for its
usefulness for monitoring disease activity and prognostication.17
For CHB patients with low level of viremia, low HBsAg levels are
associated with lower chance of hepatitic flare, cirrhosis, and
1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong and 2State Key Laboratory for Liver Research, The University of
Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Correspondence: Wai-Kay Seto, MD or Man-Fung Yuen, MD, PhD, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road,
Hong Kong, Hong Kong. E-mail: mfyuen@hkucc.hku.hk or wkseto@hku.hk
Received 23 April 2017; accepted 22 August 2017
Citation: Clinical and Translational Gastroenterology (2017) 8, e125; doi:10.1038/ctg.2017.51
Ofﬁcial journal of the American College of Gastroenterology
www.nature.com/ctg
HCC.18,19 Lower HBsAg levels, e.g. o200 IU/ml are also
associated with higher chance of HBsAg seroclearance,20,21
which is associated with favorable outcome and improved
survival.22,23 However, the decline of HBsAg level is still slow
and HBsAg seroclearance remains a rare event during nucleos
(t)ide and interferon therapy.2,24
We extended our previous 5-year entecavir study2,25 to 7
years of follow-up in a real-world cohort. The original primary aim
was to examine the rate of HBV DNA suppression, HBeAg
seroconversion, alanine aminotransferase (ALT) normalization,
virological breakthrough, and viral resistance. With the recent
increasing interest in the measurement of HBsAg and the new
development of novel HBcrAg assay, we added another
exploratoy aim to evaluate the kinetics of HBsAg and HBcrAg
over an extended period of continuous entecavir therapy.
METHODS
Patients. The present study recruited treatment-naïve CHB
patients who were started on entecavir 0.5 mg daily in the
Department of Medicine, Queen Mary Hospital, the University of
Hong Kong from July 2005 to November 2007. All patients were
HBsAg positive for at least 6 months before treatment. Patients
were started on entecavir based on the following criteria: (i)
HBeAg-positive non-cirrhotic patients with elevated ALT (upper
limit of normal o50 IU/ml) and HBV DNA 420,000 IU/ml; (ii)
HBeAg-negative non-cirrhotic patients with elevated ALT and
HBV DNA 42,000 IU/ml; and (iii) HBV DNA 42,000 IU/ml for
patients with clinical evidence of cirrhosis.
Patients with the following concomitant conditions were
excluded: hepatitis C and D infection, Wilson’s disease,
autoimmune hepatitis, primary biliary cirrhosis, and significant
intake of alcohol (20 g per day for female; 30 g per day for male).
The present study was approved by the Institutional Review
Board of the University of Hong Kong and the Hospital
Authority Hong Kong West Cluster, Hong Kong.
Patients were followed up every 3–6 months for clinical
assessment and measurement of liver biochemistry and
α-fetoprotein. Serum HBV DNA, HBeAg status, and quantitative
HBsAg levels were performed at baseline and at every year after
initiation of entecavir therapy. HBcrAg levels were measured at
baseline, the first, fifth, and seventh year of follow-up.
HBeAg seroconversion was defined by HBeAg negativity
with detectable antibody to HBeAg for at least two consecutive
follow-up. Virological breakthrough was defined as at least 1
log IU/ml increase of HBV DNA from the nadir for patients with
detectable HBV DNA levels, or HBV DNA levels increasing to
420 IU/ml for patients with previously achieved undetectable
HBV DNA levels. Viral mutational analysis was performed for
all samples with detectable viremia (HBV DNA420 IU/ml).
For patientswho opted to stop entecavir, the date of stopping of
treatment was considered as the end of follow-up for the present
study. Patients who developed signature entecavir resistance
were switched to tenofovir monotherapy. The date of change of
anti-viral therapy was considered as the end of follow-up.
Laboratory assays. Serum HBV DNA levels were measured
using Cobas Taqman assay (Roche Diagnostics, Branchburg,
NJ) with the lower limit of detection of 20 IU/ml. Resistance
profile was performed using a line probe assay (Innogenetics
NV, Gent, Belgium), with both line probe assay DR version 2
and 3 used to identify the amino acids at codons rt173, rt180,
rt240 and rt184, and rt202 and rt250, respectively. Genotypic
resistance to entecavir was defined by the presence of three
viral mutations: rtL180M, rtM204V/I, and one of the following:
rtT184S/C/G/A, rtS202G/C/I, or rtM250V. Serum HBeAg, anti-
body to HBeAg and antibody to HBsAg were measured by the
Architect Immunoassays (Abbott Laboratories, Chicago, IL).
Serum HBsAg levels were performed using Elecsys HBsAg II
Assay (Roche Diagnostics, Branchburg, NJ), with a linear range
of 0.05–52,000 IU/ml. Samples with levels higher than
52,000 IU/ml were tested at a dilution of 1:100 according to
the manufacturer’s instruction. The HBcrAg levels were
determined by the Lumipulse G HBcrAg Chemiluminescence
Enzyme Immunoassay (Fujirebio, Tokyo, Japan). The dynamic
range of the assay ranges from 1 to 1×104 kU/ml. Samples with
HBcrAg4104 kU/ml were retested at dilution of 1:100 according
to the manufacturer’s instruction. In the present study, the lower
cutoff value of HBcrAg concentration is 1 kU/ml.
Statistical analyses. Serum HBV DNA levels, HBsAg level,
and HBcrAg levels were expressed in logarithm. Continuous
variables were expressed in median (range). Comparison of
continuous variables was performed using Mann–WhitneyU-test
and Kruskal–Wallis test. Categorical variables were compared
using Pearson’s χ2 test or Fisher’s exact test as appropriate. The
rate of HBV DNA viral suppression (HBV DNA o20 IU/ml),
HBeAg seroconversion, ALT normalization, and virological
breakthrough were calculated using Kaplan–Meier analyses.
The cumulative rate of development of viral resistance was
calculated from the formula: P=1− (1−n1/N1)(1−n2/N2)…
(1−nx/Nx).26 The following factors were evaluated for their
association with undetectable HBcrAg at the seventh year in
univariate analysis: age, sex, baseline ALT, baseline HBeAg
status, baseline HBV DNA level, baseline HBsAg level, and
baseline HBcrAg level. Logistic regression model was used to
estimate odds ratios and 95% confidence interval (95% CI) of
parameters to predict undetectable HBcrAg at the seventh year.
The multivariable logistic regression model included the following
variables: age, baseline HBeAg status, baseline HBV DNA level,
baseline HBsAg level, and baseline HBcrAg level. Correlation
between clinical parameters was performed using Spearman’s
bivariate correlation. All statistical analyses were performed
using SPSS version 20 (SPSS, Chicago, IL). A two-sided P
value of o0.05 was considered statistically significant.
RESULTS
Baseline. Two hundred and twenty-two treatment-naïve
CHB patients were recruited. The baseline demographics
were shown in Table 1. In all, 222, 188, 173, 170, 167, 163,
and 160 patients were followed up for 1, 2, 3, 4, 5, 6, and 7
years, respectively. Sixty-one patients discontinued entecavir
because of various reasons listed in Table 2. One additional
patient received additional pegylated interferon prescribed by
a private doctor after 6 years of entecavir monotherapy and
thus his clinical and laboratory data were censored at 6 years
of follow-up.
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At baseline, 90 (40.5%) patients were HBeAg positive and
181 (81.5%) had elevated ALT. Seventy-one (32.0%) patients
had high HBV DNA at baseline, which was defined as HBV
DNA level of ≥ 7.3 log IU/ml (≥108 copies/ml) in our previous
study.2 Sixteen patients (7.5%) had undetectable HBcrAg
levels (≤1 kU/ml) at baseline. Two patients (0.9%) had
lamivudine resistance, whereas no patient had entecavir
resistance at baseline.
At baseline, there were good correlations betweenHBcrAg and
HBV DNA (r=0.552, Po0.001), HBcrAg and HBsAg (r=0.590,
Po0.001), and HBsAg and HBV DNA (r=0.552, Po0.001).
Virological suppression, ALT normalization, and HBeAg
seroconversion. The rates of undetectable HBV DNA and
ALT normalization were depicted in Figure 1. The rate of
undetectable HBV DNA increased from 82.9% (95% CI:
75.2–85.6) at first year to 98.7% (95% CI: 95.0–99.7) at the
seventh year (96.8% for HBeAg-positive patients, 100% for
HBeAg-negative patients). There was a more rapid decline of
HBV DNA in the group with high baseline HBV DNA, as
compared with the group with low baseline HBV DNA
(−0.965 vs. − 0.646 log IU/ml/year, Po0.001). The 7-year
rate of HBeAg seroconversion among HBeAg-positive
patients (n=90) was 82.1% (95% CI: 69.1–89.6) and that
of ALT normalization among those with elevated ALT at
baseline (n=181) was 98.3% (95% CI: 93.7–99.5) (96.7% for
HBeAg-positive patients, 100% for HBeAg-negative patients).
Virological breakthrough and resistance profile. A total of
seven patients had virological breakthroughs over 7 years of
follow-up. The virological breakthrough rate was 4.0% (95%
CI: 1.1–6.9) (8.8% for HBeAg-positive patients, 1.0% for
HBeAg-negative patients). Among these seven patients, only
two patients had genotypic resistance to entecavir at year 3
and year 4, respectively. Both patients were HBeAg-positive
at baseline. The characteristics of these two patients were
shown in our previous paper.2 The rate of genotypic
resistance to entecavir up to the seventh year was 1.2%
(95% CI: 0–2.8) (3.0% for HBeAg-positive patients, 0.0% for
HBeAg-negative patients). The remaining patients were
found to be non-compliant to entecavir treatment.
HBsAg kinetics. Of the 222 patients, 160 patients com-
pleted 7 years of follow-up. One hundred and forty-six
patients had HBsAg level measured every year. There was
a modest decline of HBsAg level over 7 years with an annual
rate of − 0.107 log IU/ml/year (range: −0.991 to 0.225)
(Po0.001).
Table 1 Baseline parameters of all 222 patients
All patients (n=222) HBeAg positive (n= 90) HBeAg negative (n=132) P value
Age (years) 47 (21–77) 41 (21–66) 50 (24–77) o0.01
Number of male 157 (70.7%) 65 (72.2%) 92 (70.0%) 0.69
HBV DNA (log IU/ml) 6.4 (3.3–48.1) 7.3 (3.3–48.1) 6.0 (3.5–48.1) o0.01
HBV DNA (≥7.3 log IU/ml) 71 (32.0%) 48 (53.3%) 23 (17.4%) o0.01
HBsAg (log IU/ml) 3.41 (0.96–5.88) 3.95 (0.96–5.88) 3.36 (0.96–5.50) o0.01
HBcrAg (log kU/ml) 2.89 (0.00–7.07) 4.57 (0.00–7.07) 2.09 (0.00–6.00) o0.01
Percentage of patients with undetectable HBcrAg 7.5% (16/214) 1.1% (1/87) 11.8% (15/127) o0.01
Albumin (g/l) 42 (22–50) 42 (22–48) 42 (22–50) 0.97
Bilirubin (μmol/l) 13 (2–216) 13 (2–67) 13 (4–216) 0.68
ALT (U/l) 92 (17–2,168) 100 (27–2,144) 81 (17–2,168) 0.25
Number of patients with elevated ALT level 181 (81.5%) 76 (84.4%) 105 (79.5%) 0.36
Abbreviations: ALT, alanine aminotransferase; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV DNA,
hepatitis B virus DNA.
Continuous variables were expressed as median (range).
P values are for the comparisons between HBeAg-positive and -negative patients.
Table 2 Details of patients who had discontinued entecavir
Reason Number of
patients
Unwilling to commit to long-term treatment or
had financial difficulty
49
Genotypic resistance to entecavir 2
Virologic breakthrougha 1
Switch to alternative anti-virals because of
pregnancy
3
HBsAg seroconversionb 1
Deathc 5
Total 61
Abbreviations: HBsAg, hepatitis B surface antigen; HBV DNA, hepatitis B
virus DNA.
aVirologic breakthrough without genotypic resistance.
bPatient who had HBsAg seroconversion and undetectable HBVDNA can opt to
stop anti-viral after discussion with physician.
cTwo patients died of hepatocellular carcinoma, 1 died of decompensated
cirrhosis, and 2 died of diseases unrelated to chronic hepatitis B infection
(carcinoma of lung and subarachnoid hemorrhage, respectively).
Figure 1 Rates of virologic suppression, alanine aminotransferase (ALT)
normalization, and genotypic resistance up to year 7.
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The median annual decline of HBsAg level was higher in
male patients compared with female patients (−0.115 vs.
−0.075 log IU/ml/year, P=0.030). The median annual
reduction of HBsAg level was higher in those with higher
baseline HBV DNA (n=46), compared with those with low
baseline HBV DNA (n=100). (−0.132 vs. − 0.096 log IU/ml/
year, P= 0.017). The median annual reduction of HBsAg level
was not statistically different among those with baseline-
positive HBeAg status and -negative HBeAg status. (−0.116
vs. − 0.105 log IU/ml/year, P=0.085).
As mentioned in our previous paper,2 one patient had
HBsAg seroclearance at the second year of follow-up. For this
patient, entecavir was stopped at the fourth year and his data
were censored afterwards. Three other patients developed
HBsAg seroclearance at the sixth year (n=1) and seventh
year (n=2) of follow-up. All four patients did not have cirrhosis
at baseline. The cumulative rate of HBsAg seroclearance was
2.5%. Their characteristics were shown in Table 3. Thirty-two
patients (21.9%) hadHBsAg level ofo200 IU/ml (or 2.3 log IU/
ml), a level highly predictive of HBsAg seroclearance in
subsequent 3 years according to our previous study.27 In
addition, another study showed that low baseline HBsAg
(o1,000 IU/ml) and a higher rate of on-treatment HBsAg
reduction (≥0.166 log IU/ml/year) were predictive of subse-
quent HBsAg seroclearance.21 The chances of achieving
HBsAg level ofo200 IU/ml after 7 years with respect to these
two parameters are depicted in Figure 2. All patients with
baseline HBsAg o1,000 IU/ml and on-treatment HBsAg
reduction of ≥0.166 log IU/ml/year had HBsAg of o200 IU/
ml at year 7. For patients who had baseline HBsAg ≥ 1,000 IU/
ml and on-treatment HBsAg reduction of o0.166 log IU/ml/
year, 95.5% of them had HBsAg ≥200 IU/ml at year 7.
HBcrAg kinetics. There was a significant decline of HBcrAg
level with treatment, with an annual change of −0.244 log kU/
ml/year (range: −0.847 to 0.183, Po0.001). The median
HBcrAg level was 2.893, 1.914, 0.895, and 0.681 log kU/ml at
baseline (n= 214), first year (n= 186), fifth year (n=156), and
seventh year of follow-up (n=147), respectively.
HBcrAg level decreased more rapidly at the first year of
follow-up compared with the reduction in subsequent years
(−0.815 vs. −0.117 log kU/ml/year, Po0.001).
The median annual decline of HBcrAg level over 7 years
was higher for patients positive for HBeAg at baseline
compared with HBeAg-negative patients (−0.428 vs. −0.151
log kU/ml/year, Po0.001). The median annual rate of
reduction of HBcrAg was higher in the patients with high
baseline HBV DNA than those with low level of HBV DNA at
baseline (−0.435 vs. −0.165 log kU/ml/year, Po0.001).
Among those who had HBcrAg measured, 11.3% (21
patients), 25.0% (39 patients), and 32.0% (47 patients) of
patients had undetectable HBcrAg at the first, fifth, and seventh
year of follow-up, respectively. Among those who had undetect-
able HBcrAg at the seventh year, 43 patients (91.5%) were
HBeAg negative at baseline. While most of the patients (97.8%)
with undetectable HBcrAg at the seventh year had undetectable
HBV DNA, only 31.7% patients (n=46) had undetectable
HBcrAg among those who had HBcrAg measured and
undetectable HBV DNA at the seventh year (n=145). Negative
baseline HBeAg status, low baseline HBcrAg level (o2 log kU/ Ta
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ml), and low baseline HBsAg level (o1,000 IU/ml) were
associated with undetectable HBcrAg at year 7 on multivariate
analysis (P=0.011, P=0.007 and P=0.013, respectively)
(Table 4a). For HBeAg-negative patients, low baseline HBcrAg
level (o2 log kU/ml) and low baseline HBsAg level (o1,000 IU/
ml) were predictive of undetectable HBcrAg at year 7 (P=0.007
and P=0.022, respectively; Table 4b). Same statistical analyses
were not performed in HBeAg-positive patients because of the
limited number of patients (n=4) achieving undetectable
HBcrAg at year 7.
Safety and clinical complications. No patient had entecavir
stopped because of side effects. Two patients were switched to
tenofovir because of documented genotypic resistance to
entecavir. Fourteen patients developed HCC. Among these
patients, six of them had cirrhosis at baseline. The median
time of development of HCC after initiation of entecavir therapy
was 47 months (range: 13–84 months). Three patients
underwent liver transplantation, with two because of HCC
and one because of decompensated cirrhosis.
DISCUSSION
Our real-life cohort showed that entecavir is a potent nucleo-
side analog. The frequency of viral suppression (with HBV
DNA of ≤20 IU/ml), HBeAg seroconversion and ALT normal-
ization at the seventh year were high: 98.7%, 82.1% and
98.3%, respectively. Genotypic resistance was only 1.2% at
year 7. Entecavir is a very effective treatment for CHB with
regard to these conventional parameters. Together with the
excellent safety profile, entecavir should remain one of the
first-line agents for long-term treatment of CHB.
There was a significant decline of HBcrAg level with
treatment, and the median rate of decline of HBcrAg was
0.244 log kU/ml/year. In contrast to the excellent suppression
of serum HBV DNA, only 32.0% of patients had undetectable
HBcrAg at the end of follow-up. Entecavir, a nucleoside
analog, inhibits the HBV reverse transcriptase, thus leading to
reduction in the production of HBV DNA-containing virion.28
However, it has no direct effect on the transcriptional activity of
viral messenger RNA from the cccDNA. Therefore, there
would be continued production of viral proteins, e.g., hepatitis
B core antigen and HBeAg for a longer period. HBcrAg would
decrease only when the transcriptional activity become lower
with natural cell death of infected hepatocytes and reduction of
infection of new uninfected hepatocytes.
The present study identified several baseline factors, which
are predictive of undetectable HBcrAg at 7 years. By multi-
variate analysis, baseline HBeAg negativity (OR 11.47,
P=0.011), HBcrAg level o2 log kU/ml (OR 5.59, P=0.007),
and baseline HBsAgo1,000 IU/ml (OR 10.72,P=0.013) were
predictive of undetectable HBcrAg at the seventh year. These
predictive factorsmay assist the selection of patients with better
outcome and provide guidance for clinical management of
CHB. The reasons are twofold. First, it has been shown that
serum HBcrAg level has a high correlation with intrahepatic
cccDNA level,8 a reservoir for viral replication. Patients
achieving undetectable HBcrAg under entecavir treatment
may indicate low cccDNA levels in their livers. This is according
to the findings of previous studies showing that low serum level
of HBcrAg at the time of cessation of lamivudine is associated
with a lower chance of reactivation of hepatitis after cessation of
lamivudine therapy.13,14 The 47 patients (32.0%) who had
undetectable HBcrAg level at the end of follow-up in the present
study could represent a group of patientswith a lower chance of
reactivation after cessation of entecavir therapy. Second, our
group have recently shown that HBcrAg level, but not HBsAg
level, was associatedwith the chance of development ofHCC in
patients with undetectable serum HBV DNA under nucleos(t)
ide analog treatment.12 Therefore, the patients in the present
study might have an even lower risk of development of HCC
while on anti-viral therapy. It was unfortunate that we could not
verify the roles of HBcrAg and HBsAg levels on the develop-
ment of HCC in the present study because only limited number
of patients (n=14) developed HCC. Therefore, it definitely
requires future studies to verify this hypothesis.
The HBsAg seroclearance rate was low (2.5%) at the
seventh year. This is because entecavir has minimal effect on
transcription and translation of HBsAg from cccDNA and
secretion of empty HBsAg to the circulation.24 HBsAg may
Figure 2 Number of patients who had hepatitis B surface antigen (HBsAg) levelo200 IU/ml at year 7 as stratified by baseline HBsAg level and on-treatment annual decline
of HBsAg.
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also be produced from integrated HBV DNA in the host.
Previous studies showed that HBsAg of o200 IU/ml was
predictive of subsequent HBsAg seroclearance in 3 years. For
patients on nucleoside analog, baseline HBsAg ofo1,000 IU/
ml and on-treatment HBsAg decline of ≥0.166 log IU/ml/year
were also predictive of subsequent HBsAg
seroclearance.21,27 In our cohort, baseline HBsAg level and
the annual decline of HBsAg could predict the chance of
having HBsAg of o200 IU/ml at the seventh year (Figure 2).
The majority of patients (95.5%) with baseline HBsAg of
≥1,000 IU/ml and decline of HBsAg ofo0.166 log IU/ml/year
had HBsAg level of ≥ 200 IU/ml at the seventh year of
entecavir treatment. These data should be interpreted with a
remark of possible limitation of “reverse analysis” on the
outcome, i.e., HBsAg o200 IU/ml at year 7. Nevertheless,
additional agentswith knockdown effects onHBsAg level, e.g.,
small interfering RNA (ARC-520)29 could be more indicative
for this group of patient to enhance HBsAg seroclearance.
One of the limitations of our study is the lack of HBV
genotype data. Most Chinese CHB patients have genotype B
or C infection. Previous studies showed that genotype is not a
major determinant of HBsAg kinetics21 and that HBcrAg
kinetics is similar in genotype B and C patients.30
In conclusion, long-term entecavir therapy achieved effec-
tive viral suppression with low drug resistance rate. However,
the decline of HBsAg with treatment was still slow. HBcrAg
(translational products of the core and e mRNA) level declined
at a relatively better rate. Baseline HBsAg level of 1,000 IU/ml
and annual decline of 0.166 log IU/ml could be used to predict
HBsAg response on entecavir treatment.
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Table 4a Factors associated with undetectable HBcrAg at the seventh year in all patients: univariate and mulitvariate analysis
Undetectable HBcrAg
(n= 47)
Detectable HBcrAg
(n= 100)
P value
(univaraite)
OR (95% CI) P value
(multivariate)
Age (years (mean, 95% CI)) 50.9 (28.7–70.8) 46.9 (21.0–66.8) 0.004 1.004 (0.933–1.081)a 0.906
Sex (M, %) 37 (78.7%) 70 (70.0%) 0.268
Raised ALTat baseline
(450 IU/ml)
38 (80.9%) 82 (82.0%) 0.867
Negative HBeAg at baseline 43 (91.5%) 50 (50.0%) o0.001 11.47 (1.75–75.29) 0.011
Baseline HBVDNAo7.8 log
IU/ml
43 (91.5%) 58 (58.0%) o0.001 0.62 (0.12–3.15) 0.561
Baseline HBsAg
o1,000 IU/ml
20 (42.6%) 4 (4.0%) o0.001 10.72 (1.65–69.53) 0.013
Baseline HBcrAg
o2 log KU/ml
24 (51.1%) 9 (9.0%) o0.001 5.59 (1.60–19.49) 0.007
Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B
surface antigen; HBV DNA, hepatitis B virus DNA.
aPer unit increase in age.
Table 4b Factors associated with undetectable HBcrAg at the seventh year in HBeAg-negative patients: univariate and mulitvariate analysis
Undetectable HBcrAg
(n= 43)
Detectable HBcrAg
(n= 50)
P value
(univaraite)
OR (95% CI) P value
(multivariate)
Age (years (mean, 95%
CI))
51.4 (48.8–54.0) 50.0 (47.6–52.3) 0.415
Sex (M, %) 33 (76.7%) 33 (66.0%) 0.255
Raised ALTat baseline
(450 IU/ml)
34 (79.1%) 38 (76.0%) 0.724
Baseline HBV DNA
o7.8 log IU/ml
41 (95.3%) 37 (74.0%) 0.005 1.16 (0.16–8.71) 0.884
Baseline HBsAg
o1,000 IU/ml
20 (46.5%) 3 (6.0%) o0.001 13.58 (1.47–125.68) 0.022
Baseline HBcrAg
o2 log KU/ml
24 (55.8%) 6 (12.0%) o0.001 6.39 (1.66–24.63) 0.007
Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B
surface antigen; HBV DNA, hepatitis B virus DNA.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
• The longest duration of follow-up for clinical outcome of
entecavir treatment in real-world cohorts is 5 years.
• Entecavir is highly effective in suppression of serum HBV
DNA in CHB patients.
• Entecavir has excellent safety profile.
WHAT IS NEW HERE
• There are cumulatively increased rates of normalization of
ALT level and HBeAg seroconversion when entecavir
treatment is extended to 7 years.
• Ninety-nine percent of patients achieved undetectable HBV
DNA level at 7 years.
• The development of drug resistance is maintained at a very
low rate of 1.2% at 7 years.
• The profile of HBcrAg level after long-term entecavir
treatment is firstly shown. There is a moderate decline of
HBcrAg (−0.244 log KU/ml/year).
• The annual decline of HBsAg level is modest (−0.107 log IU/
ml/year). Baseline HBsAg level and annual decline rate of
HBsAg can predict the chance of achieving low HBsAg level
(o200 IU/ml) at 7 years.
TRANSLATIONAL IMPACT
• The continuous decline of HBcrAg under long-term
entecavir treatment suggests that there is a reduction of
intrahepatic cccDNA.
• The relative slow decline of HBsAg suggests that additional
agents are needed for optimal treatment of CHB.
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